SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting

25 May 2023 17:05:29 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

24 May 2023 07:00:01 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

11 May 2023 12:14:45 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

03 May 2023 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference

02 May 2023 07:00:00 By Nasdaq GlobeNewswire

SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

17 Apr 2023 14:32:00 By Nasdaq GlobeNewswire

MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

17 Apr 2023 14:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors

08 Mar 2023 17:05:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

01 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

28 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors

27 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference

09 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

27 Dec 2022 06:30:07 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

22 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

03 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

29 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

10 Sep 2022 10:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces $225 Million Private Placement Financing

07 Sep 2022 09:56:00 By Nasdaq GlobeNewswire

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

07 Sep 2022 09:55:00 By Nasdaq GlobeNewswire